Search This Blog

Friday, September 7, 2018

Cyclacel Pharmaceuticals initiated at Ladenburg


Cyclacel Pharmaceuticals initiated with a Buy at Ladenburg. Ladenburg Thalmann analyst Kevin DeGeeter started Cyclacel Pharmaceuticals with a Buy rating and $6.25 price target. The analyst believes CYC065 has shown promise in Mcl-1 regulation.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)